Gujarat Terce Laboratories Ltd
₹ 56.0
0.57%
11 Jun
- close price
About
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
Key Points
- Market Cap ₹ 41.5 Cr.
- Current Price ₹ 56.0
- High / Low ₹ 94.9 / 44.5
- Stock P/E
- Book Value ₹ 8.73
- Dividend Yield 0.00 %
- ROCE 41.5 %
- ROE -14.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 47.4 to 36.9 days.
Cons
- Stock is trading at 6.41 times its book value
- The company has delivered a poor sales growth of 5.98% over past five years.
- Promoter holding is low: 37.0%
- Company has a low return on equity of -11.2% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.84 | 26.48 | 25.00 | 25.29 | 29.01 | 31.03 | 37.54 | 25.18 | 40.13 | 46.78 | 47.92 | 50.20 | |
| 27.89 | 25.70 | 24.84 | 25.21 | 28.68 | 30.54 | 36.86 | 27.77 | 39.02 | 48.94 | 46.65 | 46.31 | |
| Operating Profit | 0.95 | 0.78 | 0.16 | 0.08 | 0.33 | 0.49 | 0.68 | -2.59 | 1.11 | -2.16 | 1.27 | 3.89 |
| OPM % | 3.29% | 2.95% | 0.64% | 0.32% | 1.14% | 1.58% | 1.81% | -10.29% | 2.77% | -4.62% | 2.65% | 7.75% |
| 0.13 | 0.08 | 0.19 | 0.44 | 0.41 | 0.32 | 0.29 | 0.62 | 0.31 | 0.35 | 0.32 | 0.31 | |
| Interest | 0.41 | 0.41 | 0.38 | 0.31 | 0.23 | 0.25 | 0.29 | 0.39 | 0.40 | 0.72 | 0.68 | 0.42 |
| Depreciation | 0.33 | 0.16 | 0.19 | 0.19 | 0.19 | 0.21 | 0.24 | 0.18 | 0.28 | 0.36 | 0.37 | 0.38 |
| Profit before tax | 0.34 | 0.29 | -0.22 | 0.02 | 0.32 | 0.35 | 0.44 | -2.54 | 0.74 | -2.89 | 0.54 | 3.40 |
| Tax % | 29.41% | 72.41% | 209.09% | 150.00% | 15.62% | -25.71% | 36.36% | -0.39% | -17.57% | -42.21% | 55.56% | 128.53% |
| 0.24 | 0.09 | -0.67 | -0.01 | 0.27 | 0.43 | 0.28 | -2.52 | 0.87 | -1.67 | 0.24 | -0.98 | |
| EPS in Rs | 0.32 | 0.12 | -0.90 | -0.01 | 0.36 | 0.58 | 0.38 | -3.40 | 1.17 | -2.25 | 0.32 | -1.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 8% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -508% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 47% |
| 3 Years: | 16% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -10% |
| 3 Years: | -11% |
| Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| Reserves | 3.52 | 3.61 | 2.94 | 2.64 | 2.98 | 3.41 | 3.69 | 0.24 | 1.11 | -0.56 | -0.31 | -0.94 |
| 8.74 | 8.21 | 7.13 | 7.00 | 0.37 | 0.68 | 2.60 | 4.74 | 6.67 | 7.27 | 3.87 | 0.94 | |
| 6.24 | 7.06 | 6.98 | 6.59 | 8.69 | 7.94 | 8.80 | 9.47 | 12.19 | 14.39 | 12.29 | 15.41 | |
| Total Liabilities | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 |
| 6.13 | 6.48 | 6.34 | 6.17 | 1.88 | 2.06 | 2.29 | 2.45 | 4.29 | 3.99 | 3.69 | 3.65 | |
| CWIP | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.30 | 0.30 | 0.24 | 0.27 | 0.29 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.51 |
| 19.77 | 19.52 | 17.83 | 17.24 | 17.31 | 17.10 | 19.95 | 19.15 | 22.83 | 24.26 | 19.31 | 18.67 | |
| Total Assets | 25.92 | 26.30 | 24.47 | 23.65 | 19.46 | 19.45 | 22.51 | 21.87 | 27.39 | 28.52 | 23.27 | 22.83 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.46 | 1.38 | 0.16 | 0.24 | 4.58 | -0.61 | -1.59 | -0.16 | -0.44 | 0.03 | 2.60 | 3.06 | |
| -0.27 | 0.08 | -0.13 | 0.18 | 1.11 | -0.13 | -0.27 | -0.42 | -0.87 | 0.62 | -0.46 | 0.46 | |
| -0.74 | -0.73 | -1.43 | -0.36 | -5.39 | 0.20 | 1.72 | 1.83 | 1.53 | -0.12 | -4.08 | -2.83 | |
| Net Cash Flow | -0.55 | 0.73 | -1.39 | 0.06 | 0.29 | -0.55 | -0.14 | 1.24 | 0.22 | 0.52 | -1.94 | 0.69 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116.56 | 126.81 | 123.81 | 114.31 | 57.62 | 53.29 | 68.16 | 74.94 | 49.75 | 62.34 | 43.11 | 36.86 |
| Inventory Days | 112.27 | 142.73 | 162.86 | 150.01 | 126.33 | 114.69 | 90.00 | 136.65 | 153.90 | 83.56 | 82.12 | 71.03 |
| Days Payable | 58.79 | 88.41 | 92.30 | 59.70 | 110.67 | 85.26 | 83.44 | 104.13 | 96.22 | 110.35 | 97.39 | 69.68 |
| Cash Conversion Cycle | 170.04 | 181.14 | 194.37 | 204.61 | 73.29 | 82.72 | 74.72 | 107.46 | 107.43 | 35.56 | 27.84 | 38.21 |
| Working Capital Days | 130.61 | 132.74 | 133.59 | 108.53 | 23.15 | 33.99 | 48.32 | 48.42 | 46.57 | 25.12 | 14.70 | -5.53 |
| ROCE % | 3.80% | 3.39% | 0.87% | 1.91% | 2.95% | 5.39% | 5.79% | -15.09% | 8.26% | -14.80% | 9.72% | 41.52% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Submission of copies of Newspaper Advertisement pursuant to Regulation 47 and 52(8) of SEBI(LODR), 2015
- Results-Financial Results For The Year Ended 31.03.2025 26 May
-
Appointment Of Director
26 May - Appointment of Ms. Avani Patel as additional director effective 26/05/2025 replacing Mr. Navinchandra Patel.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
26 May - Investor Presentation for the year ended 31.03.2025
-
Board Meeting Outcome for Outcome Of Board Meeting_Audited Financial Results 31.03.2025
26 May - Approved FY 2024-25 audited results; re-appointed auditors; appointed new director; disclosed tax settlement of Rs.1341.71 lakh.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
Product Profile:[1]
Company has an extensive basket of 50 Brands (125 products) with a portfolio contributing to 10 therapeutic areas, covering multiple dosage forms like Tablets, Capsules, Oral Liquids, Ointments and Injectables.